Anemia is a common complication for patients who are undergoing chemotherapy, and one that has implications for patients’ quality of life, especially with respect to fatigue. During the European Society for Medical Oncology 2018 Congress, held October 19-23, 2018, in Munich, Germany, Jérôme Desrame, MD, reported on results of the CIROCO study, which assessed fatigue in patients with chemotherapy-induced anemia who were treated with biosimilar epoetin alfa.
Anemia is a common complication for patients who are undergoing chemotherapy, and one that has implications for patients’ quality of life, especially with respect to fatigue. During the European Society for Medical Oncology 2018 Congress, held October 19-23, 2018, in Munich, Germany, Jérôme Desrame, MD, reported on results of the CIROCO study, which assessed fatigue in patients with chemotherapy-induced anemia who were treated with biosimilar epoetin alfa.
The CIROCO study, funded by Sandoz, is a noninterventional, prospective, multicenter study of 538 adult patients who had 2 or more planned cycles of chemotherapy. The patients all had chemotherapy-induced anemia, and were receiving Sandoz’s biosimilar epoetin alfa (approved in the European Union under the brand names Epoetin Alfa Hexal, Abseamed, and Binocrit). Data were collected at inclusion, after a 2- to 3-month follow-up period, and after 4 to 6 cycles of chemotherapy.
Patients and their physicians separately assessed fatigue using a visual analogue scale (VAS) on a scale of 0 to 10; additionally, patients assessed their quality of life using the European Organization for the Research and Treatment of Cancer core quality of life questionnaire (EORTC QLQ C30).
Desrame and colleagues reported data for the subgroup of 434 patients with solid tumors. At baseline, mean hemoglobin was 9.7 (±0.8) g/dL. The mean increase in hemoglobin was 1.2 (±1.4) g/dL at 2 to 3 months of followup, and 0.4 (±1.5) g/dL after 4 to 6 cycles of chemotherapy.
In the safety population of 464 patients, 32.5% had adverse events (AEs) and 13.8% had serious AEs. However, only 3% of patients had AEs that were considered related to the study treatment.
In the full-analysis set population, between the 2- to 3-month follow-up measurement and the 4- to 6-cycle of chemotherapy measurement, the mean change in fatigue VAS score as reported by the patients was 5.2% (±92.6). The mean change in EORTC QLQ C30 score was 29.9 % (±98.0). Using the fatigue VAS, the physician assessment of fatigue was consistent with patient perceptions at all measurement timepoints.
The researchers concluded that biosimilar epoetin alfa was effective in treating these patients’ anemia, with improvements demonstrated in both hemoglobin levels and quality of life measurements.
Reference
Desrame J, et al. Correlation between fatigue evaluated with a visual analog scale (VAS) and quality of life (QoL) in cancer patients treated with biosimilar epoetin alfa for chemotherapy-induced anemia (CIA): the CIROCO study. Presented at the European Society for Medical Oncology (ESMO) 2018 Congress, October 19-23, 2018; Munich, Germany. Abstract 1790P. https://cslide.ctimeetingtech.com/esmo2018/attendee/confcal/show/session/258.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.